35 results about "Cytokine expression" patented technology

The present disclosure provides engineered induced pluripotent stem cells (iPSCs) expressing B2M-HLA fusion constructs. The present disclosure also provides iPSC-derived macrophages which overexpress IL-12. The present disclosure further provides engineered immune cells having persistent cytokine expression.

The invention provides application of injectable bioactive hydrogel in treatment of recurrent abortion, and relates to the technical field of biomedicine, and the technical key points are as follows: aldehydic hyaluronic acid and chitosan are connected in parallel, the injectable bioactive hydrogel is developed, and the hydrogel is loaded with LIF, VEGF, IL-11 and valproic acid to enhance regeneration activity. According to the application, the effect is evaluated in vitro through a specific verification experiment. Results show that the hydrogel prepared by the application shows rapid gelation, good biocompatibility and factor loading capacity, and enhances the proliferation of human endometrial stromal cells and the vascularization capacity of human umbilical vein endothelial cells. In macrophages, the expression of a proinflammatory cytokine is down-regulated, and the expression of an anti-inflammatory cytokine IL-10 is up-regulated. In conclusion, the HA-CHO / chitosan hydrogel in the application supports endometrial regeneration by synergistically promoting proliferation, angiogenesis, immune regulation and receptivity.

The invention discloses application of a pain and diarrhea prescription to regulation and control of a BLP + macrophage subgroup to treat IBS-D. The pain and diarrhea prescription contains a liver soothing component (6-10 parts of pericarpium citri reticulatae and 6-10 parts of radix saposhnikoviae) and a spleen tonifying component (10-15 parts of rhizoma atractylodis macrocephalae and 10-15 parts of radix paeoniae alba) or a combination of the liver soothing component and the spleen tonifying component according to the ratio of 1: (1-2). By promoting the expression of anti-inflammatory cytokines IL-10 and TGF-beta, inhibiting the expression of pro-inflammatory cytokines IL-6 and TNF-alpha, activating an AMPK signal channel, inhibiting an NF-kappa B signal channel and promoting the expression of colonic mucosal barrier indexes ZO1 and OCLN, a colonic mucosal barrier is repaired, and the symptoms of IBS-D abdominal pain and diarrhea are relieved. The invention also provides a pharmaceutical composition containing the key active component, and the dosage forms comprise an aqueous solution, a tablet and the like. The traditional Chinese medicine composition solves the problems of large toxic and side effects, poor compliance and unknown mechanism in the existing IBS-D treatment, is definite and safe in curative effect, and has important clinical value and scientific significance.

A treatment composition for inhibiting systemic sclerosis Vimentin mutant protein activity by using an STAT6 inhibitor, which inhibits the expression of an M2 macrophage and a profibrotic T cell which are immunocytes related to systemic sclerosis, and increases the expression of a Treg, and inhibits the expression of TGF-β, Col1a1, and α-SMA which are fibrosis factors related to systemic sclerosis. The presence of a pSTAT6 expression CD8 T cell in a fibrosis tissue has been identified, and that the expression of a pSTAT6 expression CD8 T positive cell is controlled via injection of the STAT6 inhibitor. In an animal model with increased Vimentin-specific disease symptom activity, the STAT6 inhibitor inhibits antigen-specific tissue fibrosis of systemic sclerosis with activated disease symptoms, and that the STAT6 inhibitor inhibits the expression of IL-17 cytokine expression CD8 positive TRM capable of inducing fibrosis and cell inflammation which are systemic sclerosis diseases.

The invention provides a ganoderma lucidum molecular ecological liquid extract obtained through specific fermentation and a preparation method and application thereof, and belongs to the technical field of microbial fermentation. According to the method, an improved fermentation culture medium is adopted, 5-8% of CO2 is introduced, fermentation is performed for 90-180 days at the temperature of 30-32 DEG C under the condition that the concentration of dissolved oxygen in the environment is kept to be 20-30%, and after purification, the extract of the ganoderma lucidum molecular ecological liquid is obtained. According to the myxomycete molecular ecological liquid prepared by the preparation method provided by the invention, the content of active ingredients for relieving the symptoms of the chronic obstructive pulmonary disease can be remarkably increased; moreover, an in-vitro cell experiment verifies that the extract of the ganoderma lucidum molecular ecological liquid has an inhibition effect on an A549 cell line, and an animal experiment further proves that the extract of the ecological liquid can regulate and control the expression level of proinflammatory cytokines, so that lung inflammation is inhibited, pathological injury of lung tissues is relieved, and local abnormal conditions of the lung are improved.

Disclosed are nucleic acids comprising a nucleotide sequence encoding a polypeptide comprising a cytokine, or a functional portion of the cytokine; a transmembrane-intracellular amino acid sequence or a transmembrane amino acid sequence; and an immunomodulatory imide drug (IMiD)-degradable degron, wherein the nucleotide sequence encoding the polypeptide comprises a promoter operatively associated with the nucleotide sequence encoding polypeptide. Also disclosed are related recombinant expression vectors, viral particles, host cells, populations of cells, pharmaceutical compositions, methods of treating or preventing cancer, and methods of enhancing the immune response to a cancer.

The invention belongs to the field of biotechnology and tumor immunotherapy, and particularly relates to a cancer vaccine based on attenuated listeria monocytogenes (LADS) and application of the cancer vaccine. Specifically, wild listeria monocytogenes (e.g., EGD-e) or attenuated listeria monocytogenes (LADS) are taken as an original strain, and an hly gene sequence or a fragment thereof in the original strain is replaced with polynucleotide of a fusion protein coding sequence containing LLO mutants (LLON478A + V479A) and TT856-1313, so that the recombinant attenuated listeria monocytogenes strain is obtained. Compared with wild listeria monocytogenes, the recombinant attenuated listeria monocytogenes strain has the advantages that the growth activity is not obviously changed, but the toxicity is obviously reduced; the polypeptide has cell infection ability, but has biological safety in a body and tends to colonize tumor tissue. Furthermore, the recombinant attenuated listeria monocytogenes strain can effectively inhibit the growth of cervical cancer and colon cancer, and can significantly induce immune response in a tumor microenvironment (e.g., significantly enhance cytokine expression).

A fermentation process is disclosed that produces an immunomodulatory product. The process includes combining a source of starch, a source of sugar, and a source of a trace mineral with probiotic microorganisms and fermenting aerobically and anaerobically, thereby producing an immunomodulatory product. Turmeric is added before or after fermentation. The immunomodulatory product is also disclosed. Also provided are uses of the immunomodulatory product, such as to decrease inflammation in a subject. These methods can include increasing function of natural killer cells, decreasing T cell activation, altering CD69 expression on immune cells, and / or altering cytokine expression in a subject.

The invention discloses an application of green tendon relaxing ketone in preparation of a medicine for treating rheumatoid diseases. The invention proposes and verifies that the green tendon relaxing ketone can effectively promote fibroblast-like synovial cell ferroptosis so as to inhibit synovial hyperplasia and inhibit the expression of proinflammatory cytokines so as to effectively relieve the progress of rheumatoid arthritis for the first time, and has an excellent application prospect in clinical treatment of rheumatoid diseases.

The invention discloses a lactobacillus plantarum RT1 with an anti-inflammatory effect and application of the lactobacillus plantarum RT1. The lactobacillus plantarum RT1 with the anti-inflammatory effect is screened by utilizing a J774-Dual macrophage inflammation model, the influence of the RT1 on the cell activity is evaluated, and the anti-inflammatory effect of the lactobacillus plantarum RT1 is researched. It is found that the lactobacillus plantarum RT1 significantly inhibits LPS and salmonella induced NF-kappa B activation, inhibits expression of pro-inflammatory cytokines IL-1beta, TNF-alpha and IL-6, meanwhile up-regulates the expression level of an anti-inflammatory cytokine IL-10, and maintains good cell activity; dSS-induced weight loss, occult blood, colon shortening and DAI score are significantly relieved, the MPO level and inflammatory cytokine expression are reduced, and colon tissue pathological damage is improved. The lactobacillus plantarum RT1 has the function of inhibiting intestinal inflammation, so that a new material is provided for the development of novel efficient anti-inflammatory probiotics.

This invention relates to the field of natural product pharmaceuticals, and more particularly to a spirobroussonin compound, its preparation method, and its application. The spirobroussonin C provided by this invention is isolated from the paper mulberry tree. This compound can inhibit the release of the inflammatory factor IL-13 from human keratinocytes induced by IL-4 / TNF-α, exhibiting activity superior to the clinical drug dexamethasone and without cytotoxicity. It can significantly alleviate ear dryness and excessive angiogenesis in MC903-induced atopic dermatitis mice, reduce ear swelling, epidermal thickening, and transepidermal water loss, alleviate the trend of weight loss, reduce mast cell infiltration, and inhibit the expression of serum IgE and Th2-type cytokines such as IL-13, IL-4, and TSLP in ear tissue. No glucocorticoid-like side effects such as skin atrophy or metabolic disorders were observed with Spirobroussonin C within the experimental dose range.

The present invention pertains to a Lonicera japonica flower water extract composition for preventing or treating Helicobacter pylori infection, the composition containing secoxyloganin as an active ingredient. The extract contains a specific amount of secoxyloganin, and thus exhibited excellent antibacterial effects when used on Helicobacter pylori bacteria, and exhibited excellent effects in terms of reducing Helicobacter pylori IgG antibody expression in the blood, alleviating histopathological lesions, and reducing cytokine expression when used on Helicobacter pylori-infected mice. Thus, the Lonicera japonica flower water extract of the present invention can be usefully used as a composition for preventing or treating Helicobacter pylori infection.

The present invention relates to a microbiome composition of the fermentation culture supernatant of Lactiplantibacillus plantarum KM2 strain, which has anti-inflammatory effects. It has been confirmed that the fermentation culture supernatant of the strain exhibits anti-inflammatory activities such as suppressing nitric oxide activity and regulating the expression of inflammatory cytokines, and therefore can be useful as a composition for preventing, treating, or ameliorating inflammatory diseases.

The invention discloses an application of Rubiasin A in preparation of a medicine for preventing and treating lung injury. The invention proposes and verifies that Rubiasin A can achieve the effect of protecting the activity of pulmonary epithelial cells through the synergistic effect in three directions of relieving oxidative stress injury, inhibiting expression of pro-inflammatory cytokines and recovering mitochondrial functions of cells for the first time, so that acute lung injury is effectively relieved, and the Rubiasin A is a natural medicine with great application potential.

The invention is suitable for the technical field of probiotic postbiotics, and provides application of bacillus coagulans postbiotics in improving the immune function of crucian carp. According to the embodiment of the invention, the bacillus coagulans are subjected to thermal inactivation treatment to prepare the bacillus coagulans metagen, the crucian is fed with the bacillus coagulans metagen, the immune index, the leukocyte phagocytic activity and the level of tissue immune related cytokine expression quantity of the crucian are detected, and animal experiments are carried out. The method is used for evaluating the immunological enhancement effect of the bacillus coagulans metagen, and a new idea is provided for later research and development of animal preparations.

The invention discloses an immune cell counting detection method, and belongs to the technical field of immune cell detection. According to the invention, the problem of one-sidedness of the existing detection method is solved, the immune assessment is divided into three levels, and the first level structure detects the proportion and absolute count of the basal lymphocyte subpopulation; the secondary structure deeply analyzes functional subtypes of T cells, including Th1 / Th2 / Th17, initial / memory / activated T cells and regulatory T cells; the tertiary structure is used for evaluating cytokine expression and immune checkpoint molecules; performing multi-parameter detection on the same biological sample through optimized multicolor flow cytometry, and generating a comprehensive immune assessment report; therefore, the whole state and potential problems of the immune system can be intuitively reflected, popularization and application in a clinical examination laboratory are facilitated, comprehensive and deep immune information from the number of cells to the functional state is clinically provided, and the method has important value for diagnosis, treatment monitoring and prognosis evaluation of clinical immune related diseases.

The present application relates to the field of biological medicine, and particularly relates to a recombinant herpes zoster vaccine composition and a preparation method thereof.The recombinant herpes zoster vaccine composition comprises gE protein and an adjuvant, the adjuvant is squalene oil-in-water, and the squalene oil-in-water adjuvant comprises the following concentration components: squalene: 4-5 wt%; Tween 80: 0.2-0.8 wt%; Span 85: 0.2-0.8 wt%. The vaccine composition can specifically enhance the cellular immune response to varicella-zoster virus, can significantly improve the expression of cytokines such as INF-gamma and IL-2 of CD4+ T cells in mice, and can improve the level of humoral and cellular immune response, shows high immunocompetence for preventing varicella-zoster virus infection in clinic, and the components in the vaccine composition are cheap and easy to obtain, effectively improve the yield of the vaccine, and reduce the cost of the vaccine.

The invention relates to the technical field of medicine, in particular to application of a compound in treatment of psoriasis, the compound is an AMPK activator Aldometanib, and the chemical structural formula of the compound is as shown in Figure 1. The research result shows that the Aldometanib can effectively relieve the psoriasis-like phenotype of mice, the erythema of the mice is converted from bright red to light red, the area is reduced, silver-white scales attached to the skin surface are thinned, and the psoriasis area and severity index (PASI) score is remarkably reduced. The mouse back skin lesion tissue is subjected to HE dyeing, the visible epidermis thickness is recovered to be close to the normal level through microscopic observation, inflammatory cell infiltration lesions on the superficial layer of dermis and around blood vessels are reduced, and the number is remarkably reduced. A mouse serum ELISA detection result shows that the expression of pro-inflammatory cytokines TNF alpha, IL-1beta and IL-6 is reduced. The Aldometanib disclosed by the invention is remarkable in anti-psoriasis effect, safe and non-toxic, and is expected to become a novel therapeutic drug for psoriasis.

The invention belongs to the technical field of biology, and particularly relates to application of PDPN (Podoplanin) in preparation of a medicine for treating viral myocarditis. More specifically, the invention provides a novel immunogenic peptide fragment PDPN-TE12 aiming at PDPN, a coding sequence of the novel immunogenic peptide fragment PDPN-TE12, a pharmaceutical composition containing the novel immunogenic peptide fragment PDPN-TE12, and application of the novel immunogenic peptide fragment PDPN-TE12 in prevention and / or treatment of inflammatory cardiomyopathy such as viral myocarditis. Experimental results show that the polypeptide PDPN-TE12 can significantly relieve myocardial damage of mice with viral myocarditis and inhibit inflammatory cell infiltration and inflammatory cytokine expression, so that the polypeptide PDPN-TE12 can be used as a potential drug for treating viral myocarditis, and a new candidate strategy is provided for precise targeted therapy of the disease.

This invention provides the application of carboxypyranocyanidin-3-O-glucoside, relating to the field of biomedical technology. Specifically, this invention provides the application of carboxypyranocyanidin-3-O-glucoside in the preparation of inhibitors of inflammatory cytokine expression. For inflammatory diseases, carboxypyranocyanidin-3-O-glucoside exhibits good therapeutic effects and high safety, making it worthy of widespread application.

The application discloses application of a large-mouth black bass stomach polypeptide in preparation of an antioxidant and / or immunoregulation product, relates to the field of bioactive peptides, and is characterized in that the large-mouth black bass stomach polypeptide is a polypeptide product obtained by alkaline protease enzymolysis of large-mouth black bass stomach, and components with molecular weights less than 3000 Da account for more than 98% of the total peptide amount. The polypeptide has significant DPPH free radical, hydroxyl free radical and ABTS cationic free radical scavenging capacity and reducing capacity, can promote macrophage proliferation, enhance phagocytosis, promote nitric oxide secretion, up-regulate immune-related cytokine expression, and play an immunoregulation role through activation of P38 and P44 MAPK signal pathways. The application realizes high-value utilization of large-mouth black bass processing by-products, has high product safety, and has a wide application prospect.

The present invention relates to a bispecific chimeric antigen receptor (CAR) and a preparation method thereof. The present invention first provides a bispecific chimeric antigen receptor targeting BCMA and CD7, having the following structure: S-BCMA scFv-CD7 scFv-H-TM-C-CD3ζ, wherein BCMA scFv is a BCMA antigen binding domain; CD7 scFv is a CD7 antigen binding domain; S is a signal peptide; H is a hinge region; TM is a transmembrane region; C is a co-stimulatory factor; CD3ζ is a CD3ζ intracellular signaling domain, and the chimeric antigen receptor can simultaneously bind to both BCMA and CD7 anti-tumor targets, which can significantly improve targeting and effectiveness; knocking out the immune checkpoint inhibitor gene in T cells may prevent tumor cells from triggering immune escape by specifically binding to the relevant immune checkpoint inhibitor site. The present invention selects the PD-1 / PD-L1 gene site that is most widely studied and applied for knocking out, which can greatly inhibit the tumor immune escape phenomenon. CAR-T cells are prepared by introducing the above-mentioned chimeric antigen receptor into T cells. The CAR-T cells can significantly inhibit the proliferation of leukemia cells, regulate the expression levels of cytokines such as IL-12, TNFα, and TGF-β, inhibit tumor growth in animal models, prolong the animal's survival cycle, and exert a synergistic anti-tumor effect.

The invention discloses an application of a PD-L1 single-domain antibody in preparation of a preparation for promoting hair growth or preventing and treating alopecia, belongs to the technical field of biological medicines, and particularly discloses an effect of the PD-L1 single-domain antibody in regulation and control of expression of cytokines IL-6 and Leptin so as to activate a JAK-STAT signal channel and provides a new preparation source for treatment of non-scar alopecia. The invention further provides a preparation containing the PD-L1 single-domain antibody, the side effect of an existing medicine for treating alopecia can be overcome, the treatment effect is good, and after a subject takes the medicine for 3-4 times and 8 weeks after the medicine is stopped, hair growth at the original alopecia position still continues.

The application discloses a preparation method and application of a natural active ingredient compound nanogel agent for animals, and belongs to the technical field of veterinary drug preparations. The natural active ingredient compound nanogel agent disclosed by the application is composed of natural active ingredients, a gel matrix and additional agents, is reasonable in formula, simple in process, stable in property, convenient to use and safe and long-acting. The natural active ingredient compound nanogel agent contains two synergistically acting natural active ingredients, can inhibit the proliferation of endometritis pathogenic bacteria such as staphylococcus aureus and streptococcus, and reduce the expression of pro-inflammatory cytokines at an inflammation site; meanwhile, the natural active ingredient compound nanogel agent has a certain slow-release capacity, slowly releases natural active ingredient nanoparticles easy to be taken by cells, can realize long-time residence and high-efficiency absorption of drugs at a drug administration site, and thus can enhance the action time, reduce the drug administration frequency and improve the curative effect.

Provided is a bacterial strain, the bacterial strain being a bacterial strain of Odoribacter splanchnicus, and the bacterial strain having a 16S rRNA having a nucleotide sequence as shown in SEQ ID NO: 3, or a 16S rRNA having at least 95% sequence identity thereto. The bacterial strain can promote macrophage differentiation, induce increased inflammatory cytokine expression, promote IFNβ transcription activity, and enhance immune activity. In addition, the bacterial strain can produce short-chain fatty acids including acetic acid, and inhibit histone deacetylase activity. The bacterial strain inhibits the growth of tumor cells including liver cancer and colorectal cancer, and increases the response rate of lung cancer model mice to immunotherapy drugs. The bacterial strain has good application prospects in immunoregulation and in targeting tumors.

This invention provides a *Tai Sui* molecular ecological fluid extract obtained through specific fermentation, its preparation method, and its applications, belonging to the field of microbial fermentation technology. The invention uses a modified fermentation medium, introduces 5-8% CO2, maintains a dissolved oxygen concentration of 20-30%, and ferments at 30-32℃ for 90-180 days. After purification, the *Tai Sui* molecular ecological fluid extract is obtained. The *Tai Sui* molecular ecological fluid prepared using the method provided by this invention significantly increases the content of active ingredients that alleviate symptoms of chronic obstructive pulmonary disease (COPD). Furthermore, this invention verifies through in vitro cell experiments that the extract of this *Tai Sui* molecular ecological fluid has an inhibitory effect on the A549 cell line. Further animal experiments demonstrate that the extract can regulate the expression level of pro-inflammatory cytokines, thereby inhibiting lung inflammation, alleviating pathological damage to lung tissue, and improving local lung abnormalities.

The invention discloses a gene modification method of a fusion cytokine expression element and an immunotherapy application of the fusion cytokine expression element, and relates to the technical field of gene engineering and tumor immunotherapy. Comprising the following steps that A, a preset site is selected in a genome of a host cell, a first construct AL-B-C-B-AR is provided, AL is a first homologous arm located on the upstream of the preset site, AR is a second homologous arm located on the downstream of the preset site, B is an I-SceI incision enzyme recognition site, and C is a selection marker capable of being screened in the forward direction; inserting the B-C-B sequence into the predetermined loci by homologous directional integration to form a replaceable landing frame; wherein the preset site is preferably a safe port site and a non-essential intron segment of a target functional gene, the length of the homologous arm is preferably one hundred to one thousand bases, and after integration, the correctness of the 5'end and the 3 'end is confirmed through PCR breakpoint amplification and sequencing at the same time. The whole body exposure and toxicity are reduced.

The present invention belongs to the field of biology, and relates to a vector for expressing an RSPO1 protein and the use thereof. A plasmid containing a strong cell expression promoter is constructed, a 293 cell line with efficient and stable expression is obtained by means of screening, and a downstream purification process is optimized, thereby achieving mass production of an RSPO1 recombinant protein. The obtained 293 cell line with stable expression can be cultured in suspension in a serum-free medium for growth and cytokine expression and production, thus eliminating the influence of components in serum on the product quality. Moreover, the production volume can be scaled up to 2 L, 10 L or even 300 L, eradicating the limitations of the small volume of a plate culture system. In addition, the operations of plasmid extraction and transfection are omitted from production, which can reduce the batch-to-batch variation in cytokine expression, laying a foundation for large-scale expression.

The present disclosure provides nucleic acids encoding transforming growth factor inhibitors and IL-12. Further, nucleic acids encoding the chemokine receptor CXCR3 are provided herein. Additionally, oncolytic viruses comprising the nucleic acids described herein are described herein. The compositions described herein are further described for use in the treatment of cancer. Described herein is a composition comprising a vector, the vector comprising an exogenous nucleic acid comprising a sequence encoding a cytokine or a functional variant thereof, an exogenous nucleic acid comprising a sequence encoding a chemokine receptor or a functional variant thereof, and a first promoter region upstream of the sequence encoding the chemokine receptor, causing expression of the chemokine receptor before expression of the cytokine.

The present disclosure provides engineered induced pluripotent stem cells (iPSCs) expressing B2M-HLA fusion constructs. The present disclosure also provides iPSC-derived macrophages which overexpress IL-12. The present disclosure further provides engineered immune cells having persistent cytokine expression.